Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

Isomorphic Labs United Kingdom United States of America Austria Belgium France Germany Italy Netherlands Spain Switzerland England California

in May 2024, a revolutionary AI model that can predict the structure and interactions of all of life's molecules with unprecedented accuracy. Isomorphic Labs has built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. The company is continually innovating on model architecture and developing cutting-edge capabilities to advance drug design. Isomorphic Labs is headquartered in London and has an office in Lausanne, Switzerland. 

Isomorphic Labs is advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs. 

For more information, go to www.isomorphiclabs.com and follow us on LinkedIn and X. 

View original content:https://www.prnewswire.co.uk/news-releases/isomorphic-labs-announces-600-million-funding-to-further-develop-its-next-generation-ai-drug-design-engine-and-advance-therapeutic-programs-into-the-clinic-302415534.html